Trubion Announces Initiation Of Phase 1 Study Of SBI-087 For The Treatment Of Rheumatoid Arthritis
Apr 22nd 2008Drug InformationArthritis
Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) announced that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has initiated a Phase 1 clinical trial of SBI-087, a next-generation drug candidate for the treatment of rheumatoid arthritis (RA). In collaboration with Trubion, Wyeth Pharmaceuticals is developing SBI-087 and other CD20-directed products.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
